Effects on the pharmacokinetics and pharmacodynamics in the elderly of coadministering ramipril with water, apple juice, and applesauce

Pharmaceutical Research

Volumn 13, Issue 4, 1996, Pages 639-642

  Lee, I Der ^a   Hunt, Thomas L ^b   Bradley, Charles R ^c   Copp, Carol ^a   Griffiths, Lynne ^a   Brobst Kromer, Joyce ^a  

^a SANOFI   (France)

^b Pharmaco LSR   (United States)

^c VRG International   (United States)

Author keywords

ACE inhibitor; Capsules; Elderly patients; Pharmacodynamics; Pharmacokinetics; Ramipril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; WATER;

AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADMINISTRATION, ORAL; AGED; AGING; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BEVERAGES; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAPSULES; CROSS-OVER STUDIES; FRUIT; HUMANS; MALE; RADIOIMMUNOASSAY; RAMIPRIL; THERAPEUTIC EQUIVALENCY; WATER;

EID: 0029877044     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016022827235     Document Type: Article

References (9)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:821-8 (1993).
2. A. S. Hall, C. Winter, S. M. Bogie, A. F. Mackintosh, G. D. Murray, and S. G. Ball. The acute infarction ramipril efficacy (AIRE) study: rationale, design, organization, and outcome definitions. J. Cardiovasc. Pharmacol. 18(suppl 2):S105-S109 (1991).
3. V. Teetz, R. Geiger, R. Henning, and H. Urbach. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3. 3.0]octane-3-carboxylicacid(HOE498). Arzneimittelforschung. 34(11)10B:1399-401 (1984).
4. H. Metzger, R. Maier, C. Sitter, and H. O. Stern. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3. 3.0]octane-3-carboxylic acid (HOE 498) - a new and highly effective angiotensin-I converting enzyme inhibitor. Arzneimittelforschung. 34(11)10B:1402-6 (1984).
5. H. G. Eckert, M. J. Badian, D. Gantz, H-M. Kellner, and M. Volz. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-30-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3. 3.0]octane-3-carboxylic acid (HOE 498) in rat, dog and man. Arzneimittelforschung. 34(11)10B:1435-1447 (1984).
6. P. Bunning. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (HOE 498 diacid). Comparison with captopril and enalaprilat. Arzneimittelforschung. 34(11)10B:1406-10 (1984).
7. M. K. Kottke, G. Stetsko, S. E. Rosenbaum, and C. T. Rhodes. Problems encountered by the elderly in the use of conventional dosage forms. J. Geriatr. Drug Ther. 5(2):77-92 (1990).
8. B. A. Rossi. Special considerations for drug therapy in the elderly. Pharm. Times. 55:72-3, 77-8 (1989).
9. D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-80 (1987).